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S U M M A R Y
Objectives: HIV prevalence among older people is on the increase. The aim of this study was to evaluate
the epidemiological and clinical features at diagnosis and survival of older patients.
Methods: This was a retrospective analysis of the data of 558 newly diagnosed antiretroviral-naı¨ve
patients between January 1998 and December 2008. Patients were divided into two groups according to
their age at diagnosis: 50 years (n = 103) and 18–49 years (n = 455).
Results: The most common risk factor for older patients was heterosexual contact (p < 0.013). Older
patients were more likely to suffer from hypertension (33.0% vs. 5.1%, p < 0.0005), cardiovascular disease
(20.4% vs. 2.9%, p < 0.0005), neurological disorders (11.7% vs. 5.5%, p = 0.02), renal dysfunction (12.6% vs.
5.3%, p = 0.01), and infections (66.0% vs. 49.7%, p = 0.003) than their younger counterparts, and to have
more hospital admissions during follow-up (47.5% vs. 19.6%, p < 0.0005). Older patients had a shorter
survival time (p < 0.0005). A statistically signiﬁcant increase in CD4+ cell number through time was
observed in both groups (p < 0.0005). Younger patients reached higher magnitudes of absolute numbers
of CD4+ cells during follow-up (p < 0.0005) after the initiation of antiretroviral therapy. The total
number of patients with clinical AIDS from baseline throughout the study period was also higher in the
older age group (35.9% vs. 25.0%).
Conclusions: HIV-infected people aged 50 years differ in epidemiological and clinical features to
younger HIV-infected people. The issue of increasing prevalence of HIV infection is a matter of concern
due to existing comorbidities, which probably lead to higher mortality rates and faster progression to
clinical AIDS.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In 2005, individuals aged 50 years accounted for 15% of new
HIV/AIDS diagnoses and 24% of people living with HIV/AIDS.1 The
increased prevalence among older patients has been attributed to
prolonged survival of those on highly active antiretroviral therapy
(HAART), as well as an increasing proportion of people in midlife
and late adulthood newly infected with HIV.2–6 Given the dynamic
epidemiology of HIV and the fact that HIV is nowadays considered
as a chronic disease, it is important to understand the impact of age
in these patients.7* Corresponding author. Tel.: +30 2310 994656.
E-mail address: metallidissimeon@yahoo.gr (S. Metallidis).
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in the young population, though studies from Western Europe
have presented alarming data concerning new infections in more
aged people.8 In 2007, 12.9% of newly conﬁrmed HIV cases in
Western Europe were in the population over 50 years of age, higher
than in Central or Eastern Europe.7 In Greece, the total HIV
population aged over 50 years is 15.1%, as stated in the annual
report of the Hellenic Center for Disease Control and Prevention
(HCDCP). However, the patient’s misperception of their risk and
the low suspicion for this disease by clinicians may account for the
underreporting of HIV cases among older people.9,10 Currently, no
previous studies have assessed the demographic and clinical
characteristics of the more aged HIV-infected population in Greece.
By 2015, individuals aged 50 years or more will comprise nearly
half of HIV/AIDS patients in the USA.11ses. Published by Elsevier Ltd. All rights reserved.
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regard to the clinical responses to HAART and HIV outcomes.12–16
Similarly multiple studies have shown differences in the rates of
HIV-1 RNA suppression, rates of CD4 cell recovery, and the
magnitude between the age groups.12,17,18 Some studies have
implied that survival is signiﬁcantly lower in elderly people due to
deﬁciencies of the immune system,19,20 while others have
attributed this poor outcome to frequent late presentation of
the aged people.21,22 However, there are some large studies that
have shown older people to respond similarly to HAART as their
younger counterparts.23,24 Physiological transformations attribut-
ed to ageing, including reduced immunocompetence, the presence
of comorbidities that may affect the disease progress and make its
management more complicated, and interactions among HAART
and other co-administered drugs, underline the need for the
development of age-related treatment strategies.25
Further research is certainly required to form and validate age-
speciﬁc HIV treatment guidelines.26 Currently, a few updated
publications have summarized all the relevant issues with regard
to the aged and aging HIV population and recommend general
treatment strategies for integrated management of these
patients.27,28 These articles emphasize the HIV-associated non-
AIDS conditions (HANA) and their association with advancing age.
Moreover, they underline the need for studies that will help predict
which patients are at high risk for certain complications or might
need speciﬁc interventions in a multi-morbidity context and the
need to enhance collaboration between HIV specialists and
geriatricians.27,28 The aim of this study was to assess the
prevalence rates of comorbid conditions, mortality, survival, and
immunological and virological responses in the ageing population
and moreover to detect differences in clinical and epidemiological
features at baseline between older and younger HIV patients.
2. Materials and methods
2.1. Study setting and design
Subjects were enrolled at the AHEPA University Hospital in
Thessaloniki, Greece. This hospital provides primary and specialty
care to approximately 1000 HIV-infected patients in its Infectious
Diseases Division (IDD). The IDD of AHEPA Hospital is the only one
in northern Greece and serves the majority of HIV-seropositive
patients in this geographical area. This study was a retrospective
cohort study (1998–2008).
Eligible patients had to have entered HIV care at AHEPA IDD
between January 1, 1998 and December 31, 2008, and had to have
available CD4 cell counts and HIV-RNA levels, and to have attended
for at least one visit each year during the follow-up. Other inclusion
criteria were age 18 years, to be antiretroviral-naı¨ve, and to have
a complete clinical record during the follow-up. Five hundred ﬁfty-
eight patients from the IDD who met the inclusion criteria were
included and analyzed in this study. Two age groups were deﬁned
according to the age at the time of diagnosis. The ﬁrst group
consisted of HIV-infected people aged 18–49 (n = 455), and the
second group consisted of patients aged 50 years (n = 103) at
diagnosis. The cut-off for the age (50 years) was decided on the
basis of the data of previous HIV studies, since most signiﬁcant
immunological diversities take place at that time.29–32
2.2. Variables evaluated
Demographic parameters included gender, sex, race (Greek and
non-Greek), age at diagnosis, HIV transmission risk factors
(heterosexual contact, men who have sex with men (MSM), and
injecting drug use (IDU)), number of hospitalizations after
diagnosis, cause of hospitalization, HAART intake (initiation ofHAART regimen) and time to HAART initiation from HIV diagnosis,
HIV-deﬁning morbidity (hairy leukoplakia, lymphadenopathy, oral
thrush, thrombopenia, prolonged diarrhea, herpes zoster, etc.),
HANA (progression to cirrhosis, cardiovascular disorders, lipoa-
trophy and dyslipidemia, blood disorders, infection-related
cancers, peripheral neuropathy, dementia, osteoporosis, and
nephropathy), AIDS-deﬁning diseases, and data of death. Clinical
variables also collected by review of inpatient and outpatient
medical records were: other comorbid conditions, including
hepatitis B and C, diabetes mellitus, hypertension, psychological
dysfunctions, malignancy history, and all infections other than
those that are HIV-deﬁning.
The selection of HANAs and other comorbid conditions to be
included in our analysis was based upon the most common
interactions with HIV infection and the side effects of antiretroviral
agents, according to the literature. We characterized cardiovascu-
lar disease as the presence of hypertension requiring medication,
any existing ischemic cardiovascular disorder, or former angio-
plasty. Diabetes mellitus referred to hyperglycemia treated either
with insulin or oral hypoglycemic drugs. Neurological dysfunc-
tions included peripheral neuropathy, epilepsy, dementia, and
residual clinical manifestations of a central nervous system attack
(infection, tumors), while psychological impairment was deﬁned
as any condition requiring continuous treatment (psychotropics or
antidepressants) or psychological support.
Blood disorders refer to thrombocytopenia (relative decrease of
platelets in blood below 150  109 platelets per liter) or anemia
(hemoglobin thresholds: women <12 g/dl, men <13 g/dl). Liver
impairment/damage includes severe acute chronic viral hepatic
infections (liver inﬂammation due to hepatitis B virus (HBV) or
hepatitis C virus (HCV)) or dysmetabolic function (inﬂammation of
the liver with concurrent fat accumulation in the liver in the
context of alcoholic liver disease or metabolic syndrome) and renal
damage/dysfunction refers to chronic renal insufﬁciency with
creatinine clearance 80 ml/min or proteinuria (presence of an
excess of serum protein in the urine, over 30 mg/dl) or nephrotic
syndrome (proteinuria at least 3.5 g per day per 1.73 m2 body
surface area, hypoalbuminemia, hyperlipidemia, and edema) or
any glomerular disease (inﬂammation of the glomeruli or small
blood vessels in the kidneys, regardless of cause). Hyperlipidemia
refers to high blood lipids (total cholesterol above 200 mg/dl,
triglycerides above 150 mg/dl, or both). High blood uric acid
(hyperuricemia) is considered as a blood level of uric acid above
6 mg/dl for women and 6.8 mg/dl for men.
Moreover, we evaluated the observed AIDS-free interval (time
period from HIV diagnosis to AIDS progression) and mortality
(time from HIV diagnosis to death). The 1993 revised classiﬁcation
system for HIV infection and expanded surveillance case deﬁnition
for AIDS among adolescents and adults, as well as the HIV and
Aging Consensus Project were used to specify HANAs and AIDS-
associated morbidities. Clinical AIDS refers to the onset of an
infection or a malignancy that deﬁnes the progression to the
integrated AIDS syndrome, irrelevant of CD4 cell count. Laboratory
screening included CD4 cell counts and HIV-1 RNA levels at entry
and throughout the follow-up time. Changes in the CD4 cell count
from baseline were measured at clinic visits every 6 months. CD4
counts at these intervals were estimated by averaging all CD4 cell
counts recorded within 8 weeks before and after that time period.
Late presentation or late diagnosis was considered as a CD4 cell
count <350 cells/ml at baseline visit.
2.3. Statistical analysis
Age group comparisons were performed using the Chi-square
test for qualitative data. However, if a cell of the table had few
expected cases (<5), Fisher’s exact test was used. All continuous
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U-test was used when their distributions were not normal. Kaplan–
Meier and log rank tests were used to estimate and to compare
survival functions between the two groups.
The mean increase in CD4 cell count and the mean decrease in
viral load over time were studied using a mixed analysis of
variance (ANOVA) procedure. Two-way ANOVA from random
factors was used, where age group and time were ﬁxed factors, and
patient was a random factor. This model studies the effect of age,
time, and the interaction between age and time, on CD4 cell count
or viral load. The independency and normality of residuals were
veriﬁed.
The survival analysis included Kaplan–Meier estimates and Cox
proportional hazards models using the AIDS-free interval and all-
cause mortality as the outcomes of interest. The estimated time to
an event was calculated as the time from diagnosis to each
outcome. Each outcome was analyzed using multivariate Cox
proportional hazard models using clinical and demographic
variables believed to be potential confounders. All multivariate
regressions were adjusted for all variables that were signiﬁcantly
different between age groups. All reported p-values are two-sided
and all statistical analyses were carried out using SPSS 16.0 (SPSS
Inc., Chicago, IL, USA).
3. Results
One hundred and three individuals 50 years old (18.4%) and
455 aged <50 years (81.6%) met the study criteria. The median ages
of patients aged 50 years and <50 years were 56 years
(interquartile range (IQR) 50.78) and 32 years (IQR 20.47),
respectively. Older patients were more likely to have become
infected through heterosexual contact (35.0% vs. 22.4%, p < 0.01)
than younger patients (Table 1).
More than half of the patients during the study period received
a late diagnosis, however late presentation did not differ
signiﬁcantly between the two groups (56.8% vs. 61.8%,
p < 0.565). There was no statistical difference between groups
(p = 0.479) with regard to clinical AIDS presentation at baseline.
The prevalence of infections was higher in older patients than in
their younger controls at baseline evaluation. The rate of other
comorbid conditions identiﬁed was higher in the older age group,
with the exception of infection with HCV at baseline.Table 1
Demographic and clinical characteristics of patients at baseline, stratiﬁed by age group
<50 years old
(n = 455, 81.5%
Age at diagnosis, years, mean (SD) 32.78 (7.12) 
Sex, n (%)
Male 372 (81.8) 
Female 83 (18.2) 
Nationality, n (%)
Greek 424 (93.2) 
Other 31 (6.8) 
HIV risk factor, n (%)
Heterosexual sex 102 (22.4) 
MSM 273 (60.0) 
IDU 29 (6.4) 
Unknown 51 (11.2) 
CD4 cell count, cells/ml, at baseline, mean (SD) 339.64 (243.50
CD4 cell count, cells/ml, at baseline, n (%)
<350 252 (56.8) 
350–500 87 (19.6) 
>500 105 (23.6) 
Clinical AIDS at baseline, n (%) 71 (15.6) 
Plasma viral load, log10 copies/ml, at baseline, mean (SD) 4.77 (0.94) 
IDU, injecting drug users; MSM, men having sex with men; SD, standard deviation.
a p < 0.01 for heterosexual sex.Older patients were more likely to suffer from certain
comorbidities and HANA conditions at baseline, as seen in
Table 2. They were more likely to suffer from hypertension (33%
vs. 5.1%, p < 0.0005), cardiovascular disease (20.4% vs. 2.9%,
p < 0.0005), neurological disorders (11.7% vs. 5.5%, p = 0.02), and
renal dysfunction (12.6% vs. 5.3%, p = 0.01) than their younger
counterparts.
Major events like death, clinical AIDS, hospital admission, AIDS-
deﬁning infection, HAART intake, and malignancy are described in
Table 3. Concerning mortality during the follow-up, there was a
signiﬁcant difference between the two age groups. Twenty-ﬁve
patients (5.4%) under 50 years of age died, compared to 18 patients
aged 50 years (17.4%) (p < 0.0005). Most deaths were attributed
to non-AIDS-related causes in the more aged group, in comparison
with their younger counterparts (11.65% vs. 2.64%, p < 0.0005),
while AIDS-related causes of death did not seem to differ
dramatically (5.82% vs. 2.86%, p = 0.133).
The presence of an AIDS-deﬁning infection was more often seen
in older patients (45.6% vs. 34.9%, p = 0.054) throughout the
observation period. AIDS-deﬁning malignancy did not differ
between the groups, but patients 50 years seemed to be
diagnosed with non-AIDS malignancies more frequently (11.7%
vs. 1.1%, p = 0.0005) from baseline to the end of the study period.
The most frequent types of non-AIDS-associated malignancies
were lung cancer and colon cancer for both sexes, followed by liver
cancer. In the female population, two cases of breast cancer were
also recorded. During the follow-up period, the majority of the
patients (83.7%) started antiretroviral therapy. There was no
statistically signiﬁcant difference between the two age groups
concerning the mean time until ﬁrst HAART initiation (11.7
months vs. 11.08 months, p = 0.177). Older patients were more
likely to develop clinical AIDS during follow-up (17.5% vs. 9.5%,
p = 0.03).
Older patients were signiﬁcantly more often hospitalized (more
than two hospital admissions, 47.5% vs. 19.6%, p < 0.0005) and less
likely have no hospital admissions (28.3% vs. 52.0%, p < 0.0005)
than the younger patients. The main causes of hospitalization in
the ﬁrst group were Pneumocystis jiroveci pneumonia (14%),
pneumonia of all other causes (21%), wasting syndrome (14%),
tuberculosis (9%), herpes zoster infection (7%) and Kaposi’s
sarcoma (5.5%). In older patients, the main causes of hospitaliza-
tion were P. jiroveci pneumonia (8%), pneumonia of all other causes)
50 years old
(n = 103, 18.5%)
Total population
(n = 558, 100%)
p-Value
57.74 (6.72) 37.35 (11.92) -
83 (80.6) 455 (81.5) 0.779
20 (19.4) 103 (18.5)
96 (93.2) 520 (93.2) 1.000
7 (6.8) 38 (6.8)
36 (35.0) 138 (24.7) 0.013a
54 (52.4) 327 (58.6)
1 (1.0) 30 (5.4)
12 (11.7) 63 (11.3)
) 303.86 (236.22) 332.96 (242.34) 0.179
63 (61.8) 315 (57.7) 0.213
23 (22.5) 110 (20.1)
15 (15.7) 121 (22.2)
19 (18.4) 90 (16.1) 0.479
4.91 (0.93) 4.80 (0.94) 0.208
Table 2
Comorbidities of patients at baseline, stratiﬁed by age groupa
<50 years old
(n = 455, 81.5%)
50 years old
(n = 103, 18.5%)
Total population
(n = 558, 100%)
p-Value
HIV-deﬁning morbidity, n (%) 246 (54.1) 61 (59.2) 307 (55.0) 0.381
Diabetes mellitus, n (%) 4 (0.9) 14 (13.6) 18 (3.2) <0.0005
Hypertension, n (%) 23 (5.1) 34 (33.0) 57 (10.2) <0.0005
HBV, n (%) 21 (4.6) 5 (4.9) 26 (4.7) 1.000
HCV, n (%) 23 (5.1) 4 (3.9) 27 (4.8) 0.801
CVD, n (%) 13 (2.9) 21 (20.4) 34 (6.1) <0.0005
Hyperlipidemia,b n (%) 109 (24.0) 38 (36.9) 147 (26.3) 0.009
Anemia,c n (%) 18 (4.0) 12 (11.7) 30 (5.4) 0.006
Neurological disease, n (%) 25 (5.5) 12 (11.7) 37 (6.6) 0.029
Psychological disorder, n (%) 31 (6.8) 12 (11.7) 30 (5.4) 0.103
Thrombocytopenia,d n (%) 18 (4.0) 12 (11.7) 43 (7.7) 0.073
Liver damage,e n (%) 28 (6.2) 13 (12.6) 41 (7.3) 0.034
Renal damage,f n (%) 24 (5.3) 13 (12.6) 37 (6.6) 0.014
Hyperuricemia,g n (%) 10 (2.2) 5 (4.9) 15 (2.7) 0.169
Other infections,h n (%) 226 (49.7) 68 (66.0) 294 (52.7) 0.003
CVD, cardiovascular disease; HBV, hepatitis B virus; HCV, hepatitis C virus.
a All analyses were performed using Fisher’s exact test.
b Hyperlipidemia: total cholesterol >200 mg/dl, triglycerides >150 mg/dl, or both.
c Anemia: hemoglobin <12 g/dl in women, and <13 g/dl in men.
d Thrombocytopenia: platelets <150  109/l.
e Liver damage: inﬂammation due to HCV or HBV, alcoholic liver disease, or metabolic syndrome.
f Renal damage: creatinine clearance  80 ml/min, proteinuria, nephrotic syndrome, or glomerular disease.
g Hyperuricemia: blood level of uric acid >6 mg/dl for women and >6.8 mg/dl for men.
h Other infections: all non AIDS-deﬁning infections (hepatitis virus infections excluded).
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mas (4%).
Older patients had a shorter survival time than did the younger
patients (mean time 169.1 months, 95% conﬁdence interval (CI)
154.5–183.8 vs. 205.3 months, 95% CI 200.9–209.8; p < 0.0005)
(Figure 1). The mean AIDS-free interval was shorter in older than in
younger patients (mean time 160.4 months, 95% CI 151.4–169.5 vs.
125.2 months, 95% CI 105.3–145.1; p = 0.007), as seen in Figure 2.
Twenty-ﬁve percent of younger patients were diagnosed with
clinical AIDS at 63.2 months vs. 10.8 months for older patients.
With regard to the increase in CD4+ cell numbers, both age
groups showed parallel proﬁles (age group  time: p = 0.359). A
statistically signiﬁcant increase through time was observed in both
groups (time: p < 0.0005). Younger patients had a higher magni-
tude of absolute number of CD4+ cells compared with older
patients only at 18 months (p = 0.012), 24 months (p = 0.021), and
48 months (p = 0.029) during the whole period of follow-up, as
shown in Figure 3.
With regard to the increase in CD4+ cell counts in HAART-
treated patients, both age groups responded in a similar way (age
group  time: p = 0.785). A statistically signiﬁcant increaseTable 3
Major events throughout the study period
<50 years old
(n = 455, 81.5%)
AIDS-deﬁning infection, n (%) 159 (34.9) 
Malignancy, n (%) 5 (1.1) 
AIDS-deﬁning malignancy, n (%) 20 (4.4) 
New clinical AIDS onset, n (%) 43 (9.5) 
HAART, n (%) 378 (83.1) 
Hospital admissions, n (%)
0 225 (52.0) 
1 123 (28.4) 
>2 85 (19.6) 
Mortality, n (%) 25 (5.4) 
AIDS-related death 13 (2.8) 
Non-AIDS-related death 12 (2.6) 
Total patients with clinical AIDS 114 (25) 
HAART, highly active antiretroviral therapy.
a p < 0.0005 for 0 and 2+ hospital admissions.through time was observed in both groups (time: p < 0.0005).
Younger patients had the same numbers of CD4+ cells as older ones
at each time point and during the whole period of follow-up (age
group <50 years 476.02  19.4 vs. age group 50 years
451.81  42.27; p = 0.649) (Figure 4).
Concerning the decrease in plasma viral load, no difference was
observed between the two age groups (age group  time:
p = 0.564). A statistically signiﬁcant decrease through time was
observed in both groups (time: p < 0.0005), and older patients had
lower viral load counts during follow-up (age group: p = 0.035)
(Figure 5).
Cox proportional hazard regressions were used to identify
factors associated with time to each outcome: death and
progression to clinical AIDS (Table 4). In the adjusted analysis,
older age was associated with a decreased likelihood of time to
death (adjusted hazard ratio (aHR) 4.08, 95% CI 2.02–8.24). Older
age was not statistically associated with a decreased time to
clinical AIDS (aHR 1.35, 95% CI 0.88–2.08).
Female gender was associated with an increased likelihood of
time to death (aHR 0.31, 95% CI 0.11–0.84) and increased time to
clinical AIDS (aHR 0.36, 95% CI 0.20–0.64). Non-Greek origin was50 years old
(n = 103, 18.5%)
Total population
(n = 558, 100%)
p-Value
47 (45.6) 206 (36.9) 0.054
12 (11.7) 17 (3.0) <0.0005
6 (5.8) 26 (4.7) 0.603
18 (17.5) 61 (10.9) 0.03
89 (86.4) 467 (83.7) 0.463
28 (28.3) 253 (47.6) <0.0005a
24 (24.2) 147 (27.6)
47 (47.5) 132 (24.8)
18 (17.4) 43 (7.7) <0.0005
6 (5.8) 19 (3.4) 0.133
12 (11.6) 24 (4.3) <0.0005
37 (35.9) 151 (27) 0.025
Figure 1. Test of equality of survival distributions for the different age groups.
Figure 2. Test of equality of clinical AIDS-free interval distributions for the different
age groups.
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7.02) and decreased time to clinical AIDS (aHR 1.82, 95% CI 1.02–
3.25).
CD4 cell counts between 350 and 500 cells/ml (aHR 0.46, 95% CI
0.28–0.77) and above 500 cells/ml (aHR 0.49, 95% CI 0.27–0.86)
were associated with an increased time to clinical AIDS compared
with CD4 cell counts below 350 cells/ml, but CD4 cell count did not
seem to interfere with the overall mortality.
HAART intake was associated with a decreased likelihood of
time to death (aHR 3.29, 95% CI 0.74–14.63) and decreased time toFigure 3. Comparison of CD4+ cell numbers for the diclinical AIDS (aHR 7.36, 95% CI 2.75–15.45). Cardiovascular disease
was associated with a decreased hazard of time to death (aHR 3.05,
95% CI 1.16–8.07).
4. Discussion
Since 1996, when HAART became widely available, the
morbidity and mortality of HIV-patients have decreased, andfferent age groups during the observation period.
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Also there is an increasing number of new HIV infections in older
patients due to high-risk exposures.2 The US Centers for Disease
Control and Prevention identiﬁed patients aged 50 years and older
as a separate age group, because this age group was so much older
compared with the lower mean age of patients early in the HIV
epidemic.32 The aged HIV population has been poorly described
and assessed in Greece.
In our study, the HIV population over 50 years of age in northern
Greece was 18.5%, a little bit higher than the total percentage in
Greece which is 15.1%. Older HIV-infected patients presented with
some differences in epidemiological variables compared to
younger patients. Homosexual exposure was the main route of
HIV transmission in both groups, although heterosexual contact
was signiﬁcantly higher in the older adults, as conﬁrmed in other
studies.33,34 A higher proportion of IDUs was observed in the
younger age group, and an approximately similar proportion
mentioned no risk factor for HIV transmission in both groups.
Differences in the means of transmission, since this factor is self-
reported, might indicate a fear of stigma in the advanced age group,
or a lack of awareness35,36 for sexually transmitted diseases
generally in the Greek population.37
Late presentation remains an issue for HIV patients. There are
data from studies reporting that even in the era of HAART, older
patients still delay seeking care. Studies reported in the literature
attribute this delayed access to different factors, referring to both
patients and clinicians.24,35 In our study, despite the numerical
differences in median CD4 cells counts at baseline in favor of
younger patients (306 vs. 263 cells/ml), in the number of patientswith CD4 count <350 cells/ml (56.8% vs. 61.8%) and the number of
patients with clinical AIDS at diagnosis (15.6% vs. 18.4%) there was
no statistical difference. In this speciﬁc study population, for the
decade mentioned, late presentation based on a low CD4 cell count
was a general public health issue that was not inﬂuenced by age.
No investigation on the reasons for this observation was made,
which could be a potential limitation of this study.38
At baseline evaluation, the rates of comorbid conditions
identiﬁed were higher in the older age group, as expected, with
the exception of infection with HCV. This could be attributed to the
higher number of drug addicts in the younger age group.18,39
Hypertension, diabetes mellitus, cardiovascular disease, dyslipi-
demia, anemia, neurological dysfunctions, liver damage, and renal
impairment were signiﬁcantly more frequent in the older group
than in the younger patients by the time of HIV diagnosis, a has
been described in other recent studies investigating comorbidities
in HIV patients.40,41 The progression of HIV and antiretroviral agent
metabolism could be affected by these clinical entities as well as by
their pharmaceutical regimens.42 These ﬁndings suggest that more
medical specialties should be actively involved in the care of this
speciﬁc population.
Most of the patients started HAART during the follow-up period.
There was no statistical difference between the two groups with
regards to the number of patients and the time of HAART initiation.
In our study, virological suppression did not differ by age group,
conﬁrming the results of other studies.12,43 Concerning the
immunological response, literature data are conﬂicting.13,21 With
regard to the increase in CD4+ cell numbers, both age groups
showed parallel proﬁles with a statistically signiﬁcant increase
Figure 5. Comparison of plasma viral load (log10) in the different age groups during the observation period.
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absolute numbers of CD4+ cells during follow-up. More recent
studies have conﬁrmed these results.17 CD4 cell count reconstitu-
tion has been proven to be inversely associated with age.43 Thymic
suppression is implied to be the cause of decreased immunologic
responses.44 Different clinical features and mean durations of HIV
infection in the study populations are potential variables that
might affect immunological reconstitution.45
Overall mortality was higher in the older age group. CD4 cell
counts between 350 and 500 cells/ml and above 500 cells/ml wereTable 4
Cox proportional hazards multivariate analysis of time to onset of clinical AIDS and de
Mortality 
aHR 95% CI 
Age at diagnosis
<50 years 1.00 
50 years 4.08 2.02–8.24 
Sex
Male 1.00 
Female 0.31 0.11–0.84 
Nationality
Greek 1.00 
Other 3.29 1.54–7.02 
HIV risk factor
Heterosexual sex 1.00 
MSM 0.42 0.18–0.96 
IDU 1.35 0.46–3.98 
Unknown 1.39 0.57–3.34 
HAART
No 1.00 
Yes 3.29 0.74–14.63 
CD4 cell count, cells/ml, at baseline
<350 1.00 
350–500 0.38 0.11–1.29 
>500 0.31 0.10–1.05 
Hypertension at baseline 
No 1.00 
Yes 0.14 0.02–1.10 
Diabetes mellitus at baseline 
No 1.00 
Yes 0.47 0.1–2.30 
CVD at baseline 
No 1.00 
Yes 3.05 1.16–8.07 
aHR, adjusted hazard ratio; CI, conﬁdence interval; CVD, cardiovascular disease; HAART, h
with men.associated with an increased time to clinical AIDS, compared with
CD4 cell counts below 350 cells/ml, but CD4 cell count did not play
a signiﬁcant role in the overall mortality in either population.
AIDS-related mortality did not differ between groups. The higher
overall mortality in the older patients was attributed to the non-
AIDS-related mortality aspect.
In American and European cohorts, the causes of death in HIV
patients have changed from complications of HIV to primarily non-
HIV-related causes.46 The same observation was made for
malignancies; there was no difference between groups for AIDS-ath
p-Value AIDS-free interval p-Value
aHR 95% CI
<0.0005 1.00 0.169
1.35 0.88–2.08
0.022 1.00 0.001
0.36 0.20–0.64
0.002 1.00 0.042
1.82 1.02–3.25
0.033 1.00 0.032
0.040 0.58 0.36–0.94 0.026
0.57 1.16 0.58–2.31 0.678
0.467 0.56 0.31–1.04 0.065
<0.0005 1.00 0.001
7.36 2.75–15.45
0.066 1.00 0.001
0.120 0.46 0.28–0.77 0.003
0.060 0.49 0.27–0.86 0.014
0.072 0.843
1.00
1.06 0.60–1.87
0.349 0.909
1.00
1.05 0.45–2.43
0.024 0.204
1.00
1.54 0.80–3.08
ighly active antiretroviral therapy; IDU, injecting drug users; MSM, men having sex
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patients for non-HIV malignancies (11.7% vs. 1.1%, p < 0.0005).
Recent studies have shown a dramatic increase in overall
malignancies and organ-speciﬁc malignancies, particularly lung
and liver malignancies.47 In addition, certain cancers, particularly
lung, breast, prostate, and colon cancers, increase with age.48 In our
cohort, lung and colon cancer cases were mostly recorded in both
sexes, followed by liver cancer.
A higher proportion of older patients progressed to clinical AIDS
compared to their younger counterparts (17.5% vs. 9.5%). The mean
AIDS-free interval was shorter in older than in younger patients
(mean time: 160.4 months vs. 125.2 months). This fact could be
partially explained by the fact that aging HIV people exhibit an
excess burden of multi-morbidity and a premature onset of
clinical, immunological, and functional decline, due to the HIV
virus and its antiretroviral inﬂuence.28
The elderly group of patients had a higher proportion of people
who were admitted to hospital for all causes, as conﬁrmed by other
authors too.18 In our study older patients were more frequently
hospitalized, highlighting their high morbidity and the need for
extensive care in aging seropositive people. AIDS-deﬁning infec-
tions were more frequent in the older patients, although not
surprisingly older patients had a worse survival than younger
patients and were more often hospitalized, similar conclusions to
those of previous studies,17,18 but in contrast with others
documenting a higher incidence of AIDS-deﬁning infections in
younger subjects.12
In the Cox proportional hazards multivariate analysis, age 50
years was related to a decreased time to death. Women were less
likely to have proceeded to clinical AIDS and have a fatal outcome.
Sex differences in immunological recovery, virological suppres-
sion, and clinical outcome have been observed in some previous
studies, while others have not conﬁrmed such results.49,50 Non-
Greek origin was associated with a decreased time to death and
decreased time to disease progression. Poor living conditions,
insurance issues for immigrants, and the fear of stigma could
probably account for insufﬁcient follow-up, underestimation of
health issues, and worse outcomes in this population. HAART
intake was associated with a decreased time to death and
decreased time to disease progression, probably due to the fact
that most treated patients presented with more a severe
immunological status at diagnosis. Cardiovascular disease was
associated with a decreased time to death, a fact compatible with
most studies.51
This study was a retrospective analysis, which lacks the ability
of a more targeted design. No data on the type and duration of
HAART regimen were included in our analysis. Tolerance and
adherence to HAART intake may also have had an impact on the
clinical outcome and survival of the older people; adherence data
were available for only a limited number of patients, making it
difﬁcult to draw any conclusions. Drug–drug interactions between
HAART and other agents used by older patients for non-HIV
comorbidities could have inﬂuenced survival. We used the age at
diagnosis as the main parameter, so we could not compare
individuals living with HIV at an older age to patients diagnosed
with HIV at an advanced age, and maybe we should also determine
the impact of HIV on aging in a future analysis.
As the individual with HIV grows older, other factors may
contribute to morbidity and mortality and these factors should be
taken into consideration in future analyses. Non-AIDS-deﬁning
comorbidities should be evaluated since they may be relevant to
the management of older HIV-infected patients. This increase in
age and comorbidities will increase the need for multiple
professional competences, and the sharing of specialist medical
skills. New screening test strategies for malignancies should be
developed for older HIV-infected patients. Controlled clinicalstudies should be preformed regarding the effectiveness and safety
of antiretroviral therapy in this sub-population.
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